Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System

SUZHOU, China, Aug. 1, 2023 /PRNewswire/ — Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced on July 31, 2023 that the first Chinese patient of the multi-center registration clinical trial for TaurusTrio™ Transcatheter Aortic Valve Replacement (TAVR) system has been enrolled. TaurusTrio™ is the licensed-in Trilogy™ Heart Valve System for Aortic Regurgitation (AR) from JenaValve Technology, Inc. The first implant was successfully completed by Professors Yongjian Wu and Guangyuan Song at Beijing An Zhen Hospital, Capital Medical University on July 26, 2023.

“We are pleased to have safely implanted the first patient in China with the TaurusTrio™ TAVR System,” said Dr. Yi Zhang, Chief Executive Officer of Peijia Medical. “The trial reinforces our goals of improving care in the field of cardiology and expanding TAVR systems within China. We are looking forward to our continued partnership with American company, JenaValve and presenting further data from the clinical trial at a future date.”

The clinical trial of the TaurusTrio™ TAVR system is designed to assess the safety and efficacy of the system for treating patients with native symptomatic, severe AR, who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement. The result of this clinical trial would be included in the Company’s future submission of registration application to the National Medical Products Administration (NMPA).

As of now, no transfemoral TAVR system for AR has been approved by the NMPA in China. In June 2023, TaurusTrio™ TAVR system was accepted by the Special Review and Approval Procedure for innovative medical devices of the NMPA.

In January 2022, Peijia Medical obtained an exclusive license from JenaValve for developing, manufacturing and commercializing Trilogy™ Heart Valve System in the Greater China region. On May 12, 2023, the successful completion of the first two commercial implants with the Trilogy™ Heart Valve System took place in Hong Kong.

About the Company

Peijia Medical (09996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China, and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has two generations of TAVR systems and fifteen neurointerventional devices commercialized in China and various innovative product candidates at different stage of development. For more information about Peijia visit peijiamedical.com/about

 
Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.